Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Apr 17, 2026
|
Medicus Pharma Files Orphan Drug Designation Application for SkinJect in Gorlin Syndrome
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
CHEK
Check-Cap Ltd.
The company’s legacy C-Scan system is a diagnostic equipment product category (capsule-based CRC screening).
|
$9.42M |
$1.63
+1.24%
|
|
NXGL
NEXGEL, Inc.
NXGEL generates revenue from contract manufacturing of hydrogel-based medical and consumer products.
|
$9.28M |
$1.21
+0.42%
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$9.27M |
$2.55
+2.41%
|
|
MRM
MEDIROM Healthcare Technologies Inc.
MOTHER Bracelet and related biometric sensing capabilities align with Medical Devices & Biometrics.
|
$9.25M |
$1.19
-4.03%
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$9.10M |
$4.16
+0.73%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt is a clinical-stage biotech focused on oncology immunotherapies, making 'Biotech - Oncology' a core investable theme.
|
$9.08M |
$4.87
+1.25%
|
|
PAVM
PAVmed Inc.
EsoGuard and EsoCheck are proprietary diagnostic devices/tests used for esophageal precancer detection, a direct diagnostic equipment product line.
|
$9.02M |
$9.39
+3.07%
|
|
SCND
Scientific Industries, Inc.
Medical Devices & Biometrics – automated pharmacy hardware and other medical device equipment.
|
$8.95M |
$0.54
|
|
EPIX
ESSA Pharma Inc.
Directly describes a biotech company focused on oncology drug development (masofaniten) with no revenue; core business is cancer therapeutics.
|
$8.93M |
$0.20
|
|
OSRH
OSR Holdings, Inc.
VAXIMM's lead oncology immunotherapy candidate positions OSRH in the Biotech - Oncology space.
|
$8.89M |
$0.41
-1.48%
|
|
CALC
CalciMedica, Inc.
CalciMedica's lead candidate Auxora is a CRAC channel inhibitor, i.e., an ion channel modulator.
|
$8.69M |
$0.61
-0.03%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$8.68M |
$0.35
+15.22%
|
|
NXL
Nexalin Technology, Inc.
Core product is non-invasive neuromodulation devices for brain stimulation (Gen-2 SYNC, Gen-3 HALO).
|
$8.64M |
$0.47
+1.89%
|
|
XWEL
XWELL, Inc.
XWEL's XpresTest program represents laboratory testing and advisory services, anchored by CDC collaborations and pathogen surveillance.
|
$8.58M |
$1.55
+4.36%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaCell's core focus is oncology immunotherapies, aligning with Biotech - Oncology.
|
$8.35M |
$4.40
+1.85%
|
|
VSEE
VSee Health, Inc.
Healthcare Services & Facilities; telehealth services delivered to healthcare providers.
|
$8.33M |
$0.25
+1.32%
|
|
TSBX
Turnstone Biologics Corp.
Company's core business is oncology-focused biotechnology, including immunotherapy approaches (TIL-based strategies) in solid tumors.
|
$8.21M |
$0.35
|
|
APYP
AppYea, Inc.
AppySleep devices function as medical devices/biometrics for sleep disorders.
|
$8.20M |
$0.01
|
|
RNAZ
TransCode Therapeutics, Inc.
TransCode Therapeutics operates in biotech oncology, developing cancer therapeutics.
|
$8.07M |
$8.76
+0.63%
|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$7.80M |
$0.60
+1.42%
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$7.59M |
$1.69
+3.68%
|
|
SYBX
Synlogic, Inc.
PKU is a rare metabolic disease and Synlogic's lead programs target rare diseases via a synthetic biology platform.
|
$7.42M |
$1.05
+65.48%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB develops oncology-focused cell-based therapies (Cell-in-a-Box encapsulation) aligned with Biotech - Oncology.
|
$7.38M |
$0.73
-0.19%
|
|
BNGO
Bionano Genomics, Inc.
BNGO directly manufactures and sells diagnostic instrument hardware used for Optical Genome Mapping (OGM).
|
$7.35M |
$1.55
-1.27%
|
|
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
MEDIFLY maggot debridement therapy is Cuprina's flagship wound care device/product.
|
$7.29M |
$0.34
-2.01%
|
|
PCSA
Processa Pharmaceuticals, Inc.
Processa is a oncology-focused biotech developing Next Generation Cancer therapies (NGCs), placing it squarely in Biotech - Oncology.
|
$7.02M |
$3.11
-2.20%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$7.01M |
$0.74
-0.52%
|
|
SYNX
Silynxcom Ltd.
Vital signs monitoring headset positions the product within medical devices/biometric sensing.
|
$6.98M |
$1.30
+12.50%
|
|
EVGN
Evogene Ltd.
Biomica's microbiome therapeutics program (BMC128) targets human health, fitting Immunology Therapeutics within Biotech.
|
$6.98M |
$0.79
-0.65%
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$6.94M |
$0.44
-1.77%
|
Showing page 34 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
